" class="no-js "lang="en-US"> Amneal Announces European Partnership with Orion Corporation
Friday, February 03, 2023

Amneal Announces Strategic European Partnership with Orion Corporation

Amneal Pharmaceuticals, has announced it has signed a long-term license agreement with Orion Corporation to commercialize a number of Amneal’s complex generic products. Under the partnership agreement, Orion is Amneal’s exclusive partner to bring its portfolio of complex generic programs to most parts of Europe as well as in Australia and New Zealand.

The initial portfolio will include a mix of generic products commercially available in the U.S. today, as well as select high-value pipeline products currently under development. Initial products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.

Chirag Patel and Chintu Patel, Amneal Co-Chief Executive Officers, stated, “International expansion is a key strategic priority for Amneal and today’s announcement demonstrates our commitment to execute on that. As a company, we are extremely focused on finding partners who share our same values, ethics and ambitions, and we truly could not have found a better European partner than Orion. We are excited to bring our medicines to the second largest global pharmaceutical market, and we hope that today is only the beginning of our work together.”

Liisa Hurme, President & CEO of Orion, stated, “We are delighted to announce this collaboration with Amneal, and we look forward to working together to bring these treatments to patients. This agreement expands our footprint in the European generics market as well as in Asia-Pacific region. In addition, it supports our growth strategy and is yet another fine example how Orion grows its business through high-quality strategic partnerships.”

  1. Treadwell Therapeutics Announces the Appointment of Roger Sidhu, M.D., as Chief Medical Officer Read more
  2. Personalis and Moderna Sign New Agreement to Leverage NeXT Platform™ in Personalized mRNA Cancer Vaccine Clinical Trials Read more
  3. Trelleborg to Expand its BioPharmaceutical Manufacturing Footprint in Europe Read more
  4. Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch Read more
  5. Accenture Expands Strategy Capabilities in Life Sciences with the Acquisition of Bionest Read more